ABBV vs MSFT: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Microsoft Corporation · Technology
$372.20
+32.4% upside to fair value
High Conviction
Grade A
QuantHub Verdict
MSFT has more upside to fair value
(+32.4%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MSFT |
| Current Price |
$208.05 |
$372.20 |
| Fair Value Estimate |
$217.50 |
$493.00 |
| Upside to Fair Value |
+4.5%
|
+32.4%
|
| Market Cap |
$367.9B |
$2,763.6B |
| Forward P/E |
14.9x
|
22.0x
|
| EV / EBITDA |
16.7x
|
17.5x
|
| Price / Sales |
6.1x
|
9.1x
|
| Price / FCF |
20.9x
|
35.8x
|
| Revenue Growth YoY |
+8.6%
|
+14.9%
|
| Gross Margin |
83.7%
|
68.8%
|
| Operating Margin |
34.7%
|
45.6%
|
| Return on Equity |
-129.24%
|
29.6%
|
| Dividend Yield |
3.2% |
0.94% |
| FCF Yield |
4.78%
|
2.8%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Microsoft is the world's largest software company, operating a three-pillar empire across cloud (Azure), productivity (Office 365/Teams), and personal computing (Windows/Xbox). Azure is the second-largest cloud platform globally with 24% market share and growing at 38-39% in constant currency, while Microsoft Cloud revenue crossed $168.9B in FY2025. The stock has dropped 33% from its highs to $37…
Accumulation Zones
| Metric |
ABBV |
MSFT |
| Zone Low |
$163.13 |
$370.00 |
| Zone High |
$184.88 |
$419.00 |
| In Buy Zone? |
No
|
Yes
|